Latest UK-focused news and updates.
UK-based AI drug discovery startup Converge Bio has successfully raised $25 million in a Series A funding round, with the investment led by Bessemer Venture Partners. The funding round also saw participation from high-profile executives affiliated with major tech companies, including Meta, OpenAI, and Wiz.
Converge Bio aims to leverage artificial intelligence to accelerate the drug discovery process, potentially transforming how new medications are developed. The influx of capital will be used to enhance their technology and expand their team, positioning the company to make significant advancements in the biotech sector.
The involvement of prominent figures from leading technology firms underscores the growing interest in the intersection of AI and healthcare, particularly in the UK, where innovation in biotech is rapidly evolving. This funding round is expected to bolster Converge Bio's efforts in developing cutting-edge solutions that could address unmet medical needs.
As the demand for efficient drug discovery solutions increases, Converge Bio is poised to play a crucial role in the future of healthcare technology.
Source: techcrunch.com – https://techcrunch.com/2026/01/13/ai-drug-discovery-startup-converge-bio-pulls-in-25m-from-bessemer-and-execs-from-meta-openai-and-wiz/